MedAdvisor (MDR) Stock Overview
Provides pharmacy-driven patient engagement solutions in Australia, the United States, and the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
MDR Community Fair Values
Create NarrativeSee what 18 others think this stock is worth. Follow their fair value or set your own to get alerts.
MedAdvisor Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.022 |
| 52 Week High | AU$0.33 |
| 52 Week Low | AU$0.019 |
| Beta | 1.03 |
| 1 Month Change | -15.38% |
| 3 Month Change | -57.69% |
| 1 Year Change | -92.90% |
| 3 Year Change | -90.83% |
| 5 Year Change | -94.36% |
| Change since IPO | -93.96% |
Recent News & Updates
Recent updates
MedAdvisor Limited's (ASX:MDR) Prospects Need A Boost To Lift Shares
Nov 20
Benign Growth For MedAdvisor Limited (ASX:MDR) Underpins Stock's 35% Plummet
Mar 20The Market Doesn't Like What It Sees From MedAdvisor Limited's (ASX:MDR) Revenues Yet As Shares Tumble 27%
Feb 03MedAdvisor Limited (ASX:MDR) Held Back By Insufficient Growth Even After Shares Climb 26%
Dec 07Lacklustre Performance Is Driving MedAdvisor Limited's (ASX:MDR) Low P/S
Oct 23Is MedAdvisor (ASX:MDR) Using Too Much Debt?
Jun 26Why Investors Shouldn't Be Surprised By MedAdvisor Limited's (ASX:MDR) Low P/S
Apr 24Are Investors Undervaluing MedAdvisor Limited (ASX:MDR) By 44%?
Mar 20Health Check: How Prudently Does MedAdvisor (ASX:MDR) Use Debt?
Dec 15Health Check: How Prudently Does MedAdvisor (ASX:MDR) Use Debt?
Apr 20MedAdvisor (ASX:MDR) Is Carrying A Fair Bit Of Debt
Jun 29Increases to MedAdvisor Limited's (ASX:MDR) CEO Compensation Might Cool off for now
Nov 09Is MedAdvisor (ASX:MDR) A Risky Investment?
Oct 11Is MedAdvisor (ASX:MDR) Using Too Much Debt?
Mar 08MedAdvisor (ASX:MDR) Shareholders Have Enjoyed A 41% Share Price Gain
Feb 10What Can We Make Of MedAdvisor's (ASX:MDR) CEO Compensation?
Jan 18
The Non-Executive Chairman of the Board of MedAdvisor Limited (ASX:MDR), Christopher Ridd, Just Bought A Few More Shares
Dec 22What Kind Of Investors Own Most Of MedAdvisor Limited (ASX:MDR)?
Dec 18Shareholder Returns
| MDR | AU Healthcare Services | AU Market | |
|---|---|---|---|
| 7D | 10.0% | 5.2% | 0.8% |
| 1Y | -92.9% | 12.3% | 2.1% |
Return vs Industry: MDR underperformed the Australian Healthcare Services industry which returned 12.3% over the past year.
Return vs Market: MDR underperformed the Australian Market which returned 2.1% over the past year.
Price Volatility
| MDR volatility | |
|---|---|
| MDR Average Weekly Movement | 12.9% |
| Healthcare Services Industry Average Movement | 10.3% |
| Market Average Movement | 9.6% |
| 10% most volatile stocks in AU Market | 19.2% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: MDR has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: MDR's weekly volatility (13%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | Rick Ratliff | www.medadvisorsolutions.com |
MedAdvisor Limited, together with its subsidiaries, provides pharmacy-driven patient engagement solutions in Australia, the United States, and the United Kingdom. The company offers THRiV, an omni-channel platform which provides pharmacy-driven patient and pharmacist engagement solutions to improve medication management. MedAdvisor Limited was incorporated in 2010 and is based in Woburn, Massachusetts.
MedAdvisor Limited Fundamentals Summary
| MDR fundamental statistics | |
|---|---|
| Market cap | AU$12.69m |
| Earnings (TTM) | -AU$63.32m |
| Revenue (TTM) | AU$62.99m |
Is MDR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDR income statement (TTM) | |
|---|---|
| Revenue | AU$62.99m |
| Cost of Revenue | AU$59.02m |
| Gross Profit | AU$3.97m |
| Other Expenses | AU$67.29m |
| Earnings | -AU$63.32m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.10 |
| Gross Margin | 6.31% |
| Net Profit Margin | -100.51% |
| Debt/Equity Ratio | 1,636.9% |
How did MDR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/28 09:13 |
| End of Day Share Price | 2025/11/28 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MedAdvisor Limited is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Elyse Shapiro | Canaccord Genuity |
| Lachlan Scott | MA Moelis Australia Securities Pty Ltd |
| Ian Martin | New Street Research LLP |